Incidence of brain injuries in premature infants with gestational age ≤34 weeks in ten urban hospitals in China

Chen, Hui-Jin; Wei, Kaihua; Zhou, Chuan; Yao, Yang; Yang, Yu-Jia; Fan, Xiu-fang; Gao, Xirong; Liu, Xiaohong; Qian, Jihong; Wu, Benqing; Wu, Gao-Qiang; Zhang, Qingmei; Zhang, Xiaolan

doi:10.1007/s12519-012-0395-8

Cited by 24 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14] PVL is considered today a "disease of periventricular white matter" together with post-hemorrhagic hydrocephalus and periventricular hemorrhagic infarction, being characterized by focal necrosis and diffuse injury. [15] Incidence of PVL reported in some countries was 19,8 to 34,1% for overall PVL [16,17] and 2,5 to 23% for cystic PVL. [18,19,20] Non-cystic diffuse white matter injury is a main pathological type of PVL.…”

Section: Discussionmentioning

confidence: 99%

Neurodevelopmental Outcomes in Preterm Infants With Intraventricular Hemorrhage and Periventricular Leukomalacia

Curteanu¹

2016

Neonatol. hìr. perinat. med.

View full text Add to dashboard Cite

Neonates commonly present with multiple insults, which, probably, increase the likelihood of neurological impairment. The aim of the study was to determine the incidence of brain injuries (IVH and PVL) and the survival due to these conditions in preterm infants, as well as shorter long-term neurodevelopment outcome in these newborns. Materials and methods. We have analyzed morbidity with IVH among infants born preterm from statistical forms of MoH and of Mother and Child Institute (MCI) for the period 2000-2014. We also have analyzed the MCI records to determine the IVH incidence in premature babies and the survival rate of children who suffered from IVH. Furthermore, a retrospective study of 99 preterm babies who suffered from IVH and PVL and were followed up by using Bayley-III tool was performed.

show abstract

Section: Discussionmentioning

confidence: 99%

Neurodevelopmental Outcomes in Preterm Infants With Intraventricular Hemorrhage and Periventricular Leukomalacia

Curteanu¹

2016

Neonatol. hìr. perinat. med.

View full text Add to dashboard Cite

show abstract

“…PVL, also called periventricular white matter damage (PWMD), is characterized by a loss of oligodendrocytes and their progenitor cells and is the most common antecedent of cerebral palsy and the main form of brain injury in premature infants [93,940]. Importantly, PVL accounts for 5% of premature births in China [95]. PVL involves focal periventricular necrosis and diffuse gliosis in the surrounding white matter and adversely affects social, adaptive, motor, and cognitive functions in preterm children [96,97].…”

Section: Msc-derived Secretomes For Pvl Therapymentioning

confidence: 99%

Mesenchymal stem cell-derived secretomes for therapeutic potential of premature infant diseases

et al. 2020

View full text Add to dashboard Cite

Preterm birth is a complex syndrome and remains a substantial public health problem globally. Its common complications include periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). Despite great advances in the comprehension of the pathogenesis and improvements in neonatal intensive care and associated medicine, preterm birth-related diseases remain essentially without adequate treatment and can lead to high morbidity and mortality. The therapeutic potential of mesenchymal stem/stromal cells (MSCs) appears promising as evidenced by their efficacy in preclinical models of pathologies relevant to premature infant complications. MSC-based therapeutic efficacy is closely associated with MSC secretomes and a subsequent paracrine action response to tissue injuries, which are complex and abundant in response to the local microenvironment. In the current review, we summarize the paracrine mechanisms of MSC secretomes underlying diverse preterm birth-related diseases, including PVL, BPD, NEC and ROP, are summarized, and focus is placed on MSC-conditioned media (CM) and MSC-derived extracellular vesicles (EVs) as key mediators of modulatory action, thereby providing new insights for future therapies in newborn medicine.lung function and help to remove the ventilator as soon as possible [12]. However, many studies have reported that glucocorticoid can increase the risk of adverse reactions, such as those by the nervous system, in the early or late stages, and its dose and course of treatment are not certain [13,14]. In terms of surgical treatment, preterm infants with surgical NEC are at risk of significant growth reduction and neurodevelopmental impairment (NDI), including cerebral palsy, deafness and blindness [15,16]. These sequelae and complications of prematurity-related diseases affect not only the neonatal period, but also infancy and childhood, and even adolescence and adulthood [17][18][19]. Currently, although various treatment methods have been found to achieve certain curative effects, there still exist several side effects and disputes above. Thus, it is necessary to explore and develop new therapies for the treatment and prevention of premature infant diseases.Accumulating studies have established the importance and feasibility of stem cell-based therapies to ameliorate many degenerative and inflammatory diseases. Among these stem/progenitor cell types, mesenchymal stem/stromal cells (MSCs) have received more extensive attention because they are easily extracted, exert anti-inflammatory effects, have low immunogenicity and can renew themselves. The therapeutic potential of MSCs has been demonstrated in many diseases such as cancer [20,21] and cardiovascular [22,23] and lung [24][25][26] diseases. MSCs also represent a promising and growing approach to the targeting of various pathological processes and cellular impairments underlying the major abnormalities in premature infant and preterm-associated neonatal diseases [27][28]...

show abstract

“…The evidence of PVL was found to be up to 75% in preterm infants and up to 20% in term infants in previous neuropathological studies. 5,6 PVL is defined morphologically by two histopathologic components: 1) a "focal", necrotic component in the periventricular region of the cerebral white matter and 2) a "diffuse" component characterized by reactive gliosis in the surrounding white matter. 7 PVL is the leading cause of cerebral palsy (CP) and cognitive deficits in premature infants.…”

Section: Introductionmentioning

confidence: 99%

Neonatal periventricular leukomalacia: current perspectives

Ahya¹,

Suryawanshi²

2018

RRN

View full text Add to dashboard Cite

Significant advances in the neonatal ICU have improved the survival of extreme premature neonates; with this comes the importance of intact survival. Periventricular leukomalacia (PVL) is the commonest white matter brain injury in preterm infants. It has a typical distribution at the watershed areas adjacent to the lateral ventricles. PVL occurs because of ischemic injury to periventricular oligodendrocytes of the developing brain. It can be detected by cranial ultrasonography (CUS) as initial periventricular echodensities, followed later by cystic formation. Recent magnetic resonance imaging studies have shown that it helps in early visualization of PVL and also detection of non-cystic form of PVL, which is not picked up by CUS. It is the commonest cause of cerebral palsy, intellectual impairment or visual disturbances. Currently, no medical treatment is available for PVL; prevention and close developmental follow-up are the only options.

show abstract

Incidence of brain injuries in premature infants with gestational age ≤34 weeks in ten urban hospitals in China

Cited by 24 publications

References 32 publications

Neurodevelopmental Outcomes in Preterm Infants With Intraventricular Hemorrhage and Periventricular Leukomalacia

Neurodevelopmental Outcomes in Preterm Infants With Intraventricular Hemorrhage and Periventricular Leukomalacia

Mesenchymal stem cell-derived secretomes for therapeutic potential of premature infant diseases

Neonatal periventricular leukomalacia: current perspectives

Contact Info

Product

Resources

About